.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Covington
US Department of Justice
Cipla
Deloitte
Julphar
Fish and Richardson
Baxter
Novartis
QuintilesIMS
Fuji

Generated: September 23, 2017

DrugPatentWatch Database Preview

Sodium thiosulfate - Generic Drug Details

« Back to Dashboard

What are the generic sources for sodium thiosulfate and what is the scope of sodium thiosulfate patent protection?

Sodium thiosulfate
is the generic ingredient in one branded drug marketed by Hope Pharms and Us Army, and is included in two NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Sodium thiosulfate has nine patent family members in five countries.

There are one thousand three hundred and ninety-two drug master file entries for sodium thiosulfate. One supplier is listed for this compound.

Summary for Generic Name: sodium thiosulfate

Tradenames:1
Patents:3
Applicants:2
NDAs:2
Drug Master File Entries: see list1392
Suppliers / Packagers: see list1
Bulk Api Vendors: see list50
Clinical Trials: see list2,388
Patent Applications: see list1,432
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:sodium thiosulfate at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hope Pharms
SODIUM THIOSULFATE
sodium thiosulfate
SOLUTION;INTRAVENOUS203923-001Feb 14, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Us Army
SODIUM THIOSULFATE
sodium thiosulfate
INJECTABLE;INJECTION020166-001Feb 14, 1992DISCNNoNo► Subscribe► Subscribe► Subscribe
Hope Pharms
SODIUM THIOSULFATE
sodium thiosulfate
SOLUTION;INTRAVENOUS203923-001Feb 14, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Hope Pharms
SODIUM THIOSULFATE
sodium thiosulfate
SOLUTION;INTRAVENOUS203923-001Feb 14, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Hope Pharms
SODIUM THIOSULFATE
sodium thiosulfate
SOLUTION;INTRAVENOUS203923-001Feb 14, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: sodium thiosulfate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,715,746Sodium thiosulfate-containing pharmaceutical compositions► Subscribe
9,579,345Sodium thiosulfate-containing pharmaceutical compositions► Subscribe
9,144,580Sodium thiosulfate-containing pharmaceutical compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: sodium thiosulfate

Country Document Number Estimated Expiration
Japan2012532824► Subscribe
Japan2016153360► Subscribe
World Intellectual Property Organization (WIPO)2011005841► Subscribe
Australia2010270605► Subscribe
Japan6166393► Subscribe
Japan2016106110► Subscribe
European Patent Office2451435► Subscribe
Japan5905387► Subscribe
Canada2767168► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: SODIUM THIOSULFATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
666Luxembourg► SubscribePRODUCT NAME: DASABUVIR OU UN SEL QUI EN DERIVE, Y COMPRIS DASABUVIR SODIUMMONOHYDRATE. FIRST REGISTRATION: 20150119
C0052France► SubscribePRODUCT NAME: SUGAMMADEX SODIUM; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725
C/GB08/036United Kingdom► SubscribePRODUCT NAME: MICAFUNGIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PARTICULAR MICAFUNGIN SODIUM; REGISTERED: UK EU/1/08/448/001 20080425; UK EU/1/08/448/002 20080425
2015 00014Denmark► SubscribePRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
C0055France► SubscribePRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: 434323 20130220
C/GB98/030United Kingdom► SubscribePRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204
C/GB97/078United Kingdom► SubscribePRODUCT NAME: MANGAFODIPIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR MANGAFODIPIR TRISODIUM; REGISTERED: UK EU/1/97/040/001 19970522; UK EU/1/97/040/002 19970522
C/GB02/042United Kingdom► SubscribePRODUCT NAME: ERTAPENEM ((1R,5S,6S,8R,2'S,4'S)-2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)-6-(1-HYDROXYETHYL)-1-METHYLCARBAPENEM-3-CARBOXYLIC ACID), A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF, ESPECIALLY AS THE MONOSODIUM SALT ERTA; REGISTERED: UK EU/1/02/216/001 20020418
C/GB98/040United Kingdom► SubscribePRODUCT NAME: RABEPRAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE SODIUM SALT; REGISTERED: UK 10555/0010 19980508; UK 10555/0008 19980508
14/058Ireland► SubscribePRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REGISTRATION NO/DATE: EU/1/14/924/001-002 20140516
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Federal Trade Commission
Harvard Business School
US Army
Boehringer Ingelheim
UBS
Cipla
Fish and Richardson
Novartis
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot